Cited by 602Blood Coagulation and Thrombosis MechanismsAcute Myocardial Infarction ResearchBlood properties and coagulation

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor

Thögersen, Anna M., Jansson, Jan-Håkan, Boman, Kurt, Nilsson, Torbjörn K., Weinehall, Lars, Huhtasaari, Fritz, Hallmans, Göran·1998·Circulation

DOI 10.1161/01.cir.98.21.2241

Open this paper in CoChat — free account

Abstract

Background —In patients with established ischemic heart disease, prospective cohort studies have indicated that plasminogen activator inhibitor (PAI-1), the inhibitor of the fibrinolytic system, may predict cardiovascular events. So far, there have been no primary prospective studies of PAI-1. Methods and Results —The aim of the present study was to test whether plasma levels of PAI-1, tissue-type plasminogen activator (tPA), von Willebrand factor (vWF), and thrombomodulin (TM) could predict the occurrence of a first acute myocardial infarction (AMI) in a population with high prevalence of coronary heart disease by use of a prospective nested case-control design. Mass concentrations of PAI-1 and tPA were significantly higher for the 78 subjects who developed a first AMI compared with the 156 references matched for age, sex, and sampling time; for tPA, this increase was independent of smoking habits, body mass index, hypertension, diabetes, cholesterol, and apolipoprotein A-I. The ratio of quartile 4 to 1 for tPA was 5.9 for a patient to develop a first AMI. The association between tPA and AMI was seen in both men and women. Increased levels of vWF were associated with AMI in a univariate analysis. High levels of TM were associated with AMI in women but not in men. Conclusions —The plasma levels of PAI-1, tPA, and vWF are associated with subsequent development of a first AMI; for PAI-1 and tPA, this relation was found in both men and women. For tPA but not for PAI-1 and vWF, this association is independent of established risk factors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.cir.98.21.2241

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coronary Plaque Disruption
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
Thompson, S. G., Kienast, J., Pyke, S., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,819
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G. H., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711
Endogenous tissue-type plasminogen activator and risk of myocardial infarction
Ridker, P. M., Vaughan, D. E., Manson, J., Hennekens, C. H., & Stampfer, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90998-v · Cited by 580
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
Juhan-Vague, I., Pyke, S., Alessi, M., Jespersen, J., Haverkate, F., & Thompson, S. G. (1996) · Circulation · doi:10.1161/01.cir.94.9.2057 · Cited by 551
von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.
Jansson, J., Nilsson, T., & Johnson, O. (1991) · Heart · doi:10.1136/hrt.66.5.351 · Cited by 356
Self-citation
Clearance of Tissue Plasminogen Activator (TPA) and TPA/Plasminogen Activator Inhibitor Type 1 (PAI-1) Complex: Relationship to Elevated TPA Antigen in Patients With High PAI-1 Activity Levels
Chandler, W. L., Alessi, M. C., Aillaud, M. F., Henderson, P., Vague, P., & Juhan-Vague, I. (1997) · Circulation · doi:10.1161/01.cir.96.3.761 · Cited by 245

Show all 30 references

Research works printed but not linked: 10

10.1161/circ.83.1.1984895 · DOI
10.1161/circ.92.3.657 · DOI
10.1161/circ.94.9.2052 · DOI
10.1161/circ.90.1.8026046 · DOI
Amiral J, Adam M, Mimilia F, Larrivaz I, Chambrette B, Boffa MC. A new assay for soluble forms of thrombomodulin in plasma. Thromb Haemostas. 1991;947:65. Abstract.
10.1161/atv91.12.9.1525121 · DOI
10.1161/circ.88.5.8222095 · DOI
10.1161/circ.94.9.2057 · DOI
10.1161/atvb.15.9.1432 · DOI
10.1161/circ.96.3.761 · DOI

Sorted by citations

Items 301–400 of 597

The Salutary Effects of Catalpol on Diesel Exhaust Particles-Induced Thrombogenic Changes and Cardiac Oxidative Stress, Inflammation and Apoptosis
Nemmar, A., Beegam, S., Zaaba, N. E., Alblooshi, S., Alseiari, S., & Ali, B. H. (2022) · Biomedicines · doi:10.3390/biomedicines10010099 · Cited by 21
“Moreover, an increase in PAI-1 concentrations of plasma has been associated with inflammation and atherosclerosis and has also been recognized as a risk factor for ischemic cardiovascular events [40].”
Background
The Effect of Subclinical Hypothyroidism on Coagulation and fibrinolysis: A Systematic Review and Meta-Analysis
Xu, Q., Wang, Y., Xue, S., Zhang, Y., Fan, Q., & Zhang, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.861746 · Cited by 20
von Willebrand Factor and Oxidative Stress Parameters in Acute Coronary Syndromes
Koprivica, Z., Djordjevic, D. Z., Vuletic, M., Zivkovic, V. I., Barudzic, N. S., Andjelkovic, N. V., Djuric, D. M., Iric-Cupic, V., Krkeljić, J., & Jakovljevic, V. L. (2011) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2011/918312 · Cited by 20
“Many studies found increased relative risk in subjects with the highest levels of vWf [6, 38, 39], but in the majority of studies, the association between vWf and CHD risk disappeared after adjustment for conventional risk factors [8, 9].”
Background
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study
Kinlay, S., Schwartz, G. G., OLSSON, A. G., Rifai, N., Bao, W., Libby, P., & Ganz, P. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.020 · Cited by 20
Prognostic impact of haemostatic derangements in chronic heart failure
Vene, N., Salobir, B., Šebeštjen, M., Šabović, M., Keber, I., & Jug, B. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-11-0721 · Cited by 21
“620 [37–1076] μg/l; p=0.”
Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome
Imperatore, F., Cuzzocrea, S., Lucia, D. D., Sessa, M., Rinaldi, B., Capuano, A., Liguori, G., Filippelli, A., & Rossi, F. (2006) · Intensive Care Medicine · doi:10.1007/s00134-006-0367-3 · Cited by 20
“myocardial infarction, ischemic stroke [32, 33 , 34, 35, 36] and, although controversially, peripheral artery disease [37, 38].”
Thrombosis in VonWillebrand disease
Qureshi, W., Hassan, S., Dabak, V. S., & Kuriakose, P. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.09.005 · Cited by 19
“[25] suggested an association between VWF levels and risk of CAD, however this association was not statistical significant after adjustment for the risk factors.”
Background
Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome
Lindholm, Å., Bixo, M., Eliasson, M., Hudecova, M., Arnadottir, R., Holte, J., & Poromaa, I. S. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.487592 · Cited by 19
“Plasminogen activator inhibitor 1 (PAI-1) and tissue plasminogen activator (tPA) mass play major roles in the fibrinolytic system and are associated with risk for myocardial infarction in both men and women [17].”
Background
Weight loss induced by 6‐month lifestyle intervention improves early endothelial activation and fibrinolysis in obese adolescents
Huang, F., Del-Rio-Navarro, B. E., de Castro, G. T. M., Torres-Alcántara, S., Monge, J. J. L. S., Ontiveros, J. A. P., Navarro-Olivos, E., Barron, M., Lopéz, A. R., Villafaña, S., et al. (2010) · Child Care Health and Development · doi:10.1111/j.1365-2214.2010.01173.x · Cited by 19
Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease
Bilgir, O., Bilgir, F., Bozkaya, G., & Çalan, M. (2013) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000009 · Cited by 19
Haemostatic factors in women with history of Preeclampsia
Portelinha, A., Cerdeira, A. S., Belo, L., Braga, J. S., Tejera, E., Pinto, A., Pinto, F., Areias, M. J., Patrı́cio, B., & Rebelo, I. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.10.005 · Cited by 19
“[28] Thögersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G.”
Background
TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit
Cellai, A. P., Antonucci, E., Liotta, A. A., Fedi, S., Marcucci, R., Falciani, M., Giglioli, C., Abbate, R., & Prisco, D. (2005) · Thrombosis Research · doi:10.1016/j.thromres.2005.10.006 · Cited by 19
Effects of oxidized and glycated low-density lipoproteins on transcription and secretion of plasminogen activator inhibitor-1 in vascular endothelial cells
Ma, G. M., Halayko, A. J., Stelmack, G. L., Zhu, F., Zhao, R., Hillier, C. T., & Shen, G. X. (2006) · Cardiovascular Pathology · doi:10.1016/j.carpath.2005.08.012 · Cited by 19
Determinants of Plasminogen Activator Inhibitor-1 in South Asians with Ischaemic Stroke
Kain, K., Young, J. B., Bamford, J., Bavington, J., Grant, P. J., & Catto, A. J. (2002) · Cerebrovascular Diseases · doi:10.1159/000064732 · Cited by 19
The association between sleep characteristics and prothrombotic markers in a population-based sample: Chicago Area Sleep Study
Tosur, Z., Green, D., De Chavez, P. J., Knutson, K. L., Goldberger, J. J., Zee, P., Liu, K., Kim, K.-Y., & Carnethon, M. R. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.04.005 · Cited by 21
Insulin resistance is associated with at least threefold increased risk for prothrombotic state in severely obese youngsters
Galli‐Τsinopoulou, A., Kyrgios, I., Maggana, I., Giannopoulou, E. Z., Kotanidou, E. P., Stylianou, C., Papadakis, E. S., Korantzis, I., & Varlamis, G. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-010-1370-9 · Cited by 18
“The importance of the above findings has already been confirmed by prospective studies that have described PAI-1-Ag as a predictor for future cardiovascular events [ 60 ] and the onset of type 2 diabetes [23].”
Result
Molecular mechanism of two nanobodies that inhibit PAI‐1 activity reveals a modulation at distinct stages of the PAI‐1/plasminogen activator interaction
Sillen, M., Weeks, S. D., Zhou, X., Komissarov, A. A., Florova, G., Idell, S., Strelkov, S. V., & Declerck, P. J. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14716 · Cited by 18
“The SI, defined as the number of moles of PAI-1 required for the inactivation of one mole of PA, for the reaction between free or monomeric Vn-bound PAI-1-wt and two-chain tPA (tctPa) or uPA (tcuPA) (all from Molecular Innovations Inc) in the presence of Nbs was estimated by sodium dodecyl sulfate–polyacrylamide gel e…”
BackgroundInfluential
Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance
Chang, M., Lin, Y., Pao, L., Huang, H.-C., & Chiu, C. (2017) · Scientific Reports · doi:10.1038/srep42503 · Cited by 18
Modulation of Serpin Reaction through Stabilization of Transient Intermediate by Ligands Bound to α-Helix F
Komissarov, A. A., Zhou, A., & Declerck, P. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702089200 · Cited by 18
PAI‐1 5G/5G genotype is an independent risk of intracranial hemorrhage in post‐lysis stroke patients
Szegedi, I., Nagy, A. C., Székely, E. G., Czuriga‐Kovács, K. R., Sarkady, F., Lánczi, L., Berényi, E. L., Csiba, L., & Bagoly, Z. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50923 · Cited by 18
Effects of Short-Term Exercise Training on Plasminogen Activator Inhibitor (PAI-1)
Bodary, P. F., YASUDA, N., WATSON, D. D., Brown, A. S., DAVIS, J. M., & Pate, R. R. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000093751.82616.f0 · Cited by 18
Alcohol drinking and cardiac risk
Buemann, B., Dyerberg, J., & Astrup, A. V. (2002) · Nutrition Research Reviews · doi:10.1079/nrr200235 · Cited by 18
“A recent prospective case–control study which compared patients who subsequently experienced their first MI with a matched reference group suggests that a high PAI-1 level may be associated with a high risk of CHD (Thögersen et al. 1998).”
Reduced risk of myocardial infarction related to active commuting: inflammatory and haemostatic effects are potential major mediating mechanisms
Wennberg, P., Wensley, F., Johansson, L., Boman, K., Angelantonio, E. D., Rumley, A., Lowe, G. D. O., Hallmans, G., & Jansson, J. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32832f3b11 · Cited by 17
Self-citation
Von Willebrand factor antigen levels predict major adverse cardiovascular events in patients with carotid stenosis of the ICARAS study
Kovacevic, K. D., Mayer, F. J., Jilma, B., Buchtele, N., Obermayer, G., Binder, C. J., Blann, A. D., Minar, E., Schillinger, M., & Hoke, M. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.09.003 · Cited by 17
Von Willebrand factor predicts major bleeding and mortality during oral anticoagulant treatment
Lind, M. M., Boman, K., Johansson, L., Nilsson, T. K., Järvholm, L. S., & Jansson, J.-H. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02418.x · Cited by 17
Self-citation
Prothrombotic markers in asymptomatic dyslipidemic subjects
Karásek, D., Vaverková, H., Halenka, M., Jackuliaková, D., Fryšák, Z., Slavík, L., & Novotný, D. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0474-4 · Cited by 17
“Von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) are molecules with haemostatic impact, which seem to play a role as indicators of cardiovascular disease and to predict increased risk of acute events [12–19].”
Background
Interaction among 5,10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients
Ağırbaşlı, D., Ağırbaşlı, M. A., Williams, S. M., & Phillips, J. A. (2006) · Coronary Artery Disease · doi:10.1097/00019501-200608000-00003 · Cited by 17
Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients
Gin, H., Roudaut, M., Vergnot, V., Baillet, L., & Rigalleau, V. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70064-2 · Cited by 17
“PAI-1 is a strong inhibitor of the fibrinolytic system and has been shown to be a predictive factor of myocardial infarction [10].”
Background
Relation of autonomic activity to plasminogen activator inhibitor-1 plasma concentration and the role of body mass index
von Känel, R., Nelesen, R. A., Ziegler, M. G., Mausbach, B. T., Mills, P. J., & Dimsdale, J. E. (2007) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3281139c67 · Cited by 17
Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women
Martı́nez, C., Basurto, L., Zárate, A., Saucedo, R., Gaminio, E., & Collazo, J. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.03.011 · Cited by 17
Plasminogen Activator Inhibitor-1 and the Calculus of Mortality After Myocardial Infarction
Vaughan, D. E. (2003) · Circulation · doi:10.1161/01.cir.0000082929.85234.e7 · Cited by 17
Correlation between omental TNF-α protein and plasma PAI-1 in obesity subjects
Cao, Y. L., Wang, Y. X., Wang, D. F., Meng, X., & Zhang, J. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.05.033 · Cited by 16
Resistin regulates the expression of plasminogen activator inhibitor-1 in 3T3-L1 adipocytes
Ikeda, Y., Tsuchiya, H., Hama, S., Kajimoto, K., & Kogure, K. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.076 · Cited by 16
Association of Blood Pressure and Fitness With Levels of Atherosclerotic Risk Markers Pre-Exercise and Post-exercise
von Känel, R., Hong, S. J., Pung, M. A., & MILLS, P. (2007) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2007.01.005 · Cited by 16
Treatment-related cardiovascular toxicity in long-term survivors of testicular cancer
Gugic, J., Zaletel, L. Z., & Oblak, I. (2016) · Radiology and Oncology · doi:10.1515/raon-2016-0021 · Cited by 16
“17 (2000) 87 Before 1987a 14 (10 to 20) 27 (17-36) 42 (30-50) SIR=7.”
Profibrinolytic Effect of the Epigenetic Modifier Valproic Acid in Man
Saluveer, O., Larsson, P., Ridderstråle, W., Hrafnkelsdóttir, Þ. J., Jern, S., & Bergh, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107582 · Cited by 16
“Both t-PA and PAI-1 levels are risk factors for a first myocardial infarction [9,29,30], and they are also significant risk markers for recurrent myocardial infarction [31,32].”
Background
Fibrinolysis and von Willebrand factor in Alzheimer's disease and vascular dementia – a case-referent study
Hagnelius, N.-O., Boman, K., & Nilsson, T. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2009.10.001 · Cited by 16
Self-citation
Thrombophilia
Heit, J. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00014-2 · Cited by 16
Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease – a 13-year follow-up
Niessner, A., Graf, S., Nikfardjam, M., Speidl, W. S., Huber-Beckmann, R., Zorn, G., Wojta, J., & Huber, K. (2003) · Thrombosis and Haemostasis · doi:10.1160/th02-10-0185 · Cited by 16
“Several prospective clinical studies have demonstrated that elevated t-PA antigen is the strongest predictive marker of the endogenous fibrinolytic system for coronary events (14-20).”
Background
Role of c-Jun NH2-terminal kinase in G-protein-coupled receptor agonist-induced cardiac plasminogen activator inhibitor-1 expression
Omura, T., Yoshiyama, M., Matsumoto, R., Kusuyama, T., Enomoto, S., Nishiya, D., Izumi, Y., Kim, S., Ichijo, H., Motojima, M., et al. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.01.008 · Cited by 16
The effects of polymorphisms in genes from the renin–angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context
Asselbergs, F. W., Williams, S. M., Hebert, P. R., Coffey, C. S., Hillege, H. L., Snieder, H., Navis, G. J., Vaughan, D. E., van Gilst, W. H., & Moore, J. H. (2007) · Human Genetics · doi:10.1007/s00439-007-0400-9 · Cited by 15
“Plasma t-PA and PAI-1 levels are identiWed as risk factors for thrombo-embolic disease (Jansson et al. 1993; Thogersen et al. 1998; Hamsten et al. 1987; Mannucci et al. 2005).”
Background
Acute Ingestion of Long-Chain (n-3) Polyunsaturated Fatty Acids Decreases Fibrinolysis in Men with Metabolic Syndrome
Møntegaard, C., Tulk, H. M. F., Lauritzen, L., Tholstrup, T., & Robinson, L. E. (2009) · Journal of Nutrition · doi:10.3945/jn.109.111427 · Cited by 15
Endothelial haemostatic markers in members of families with familial combined hyperlipidemia
Karásek, D., Vaverková, H., Halenka, M., Slavík, L., & Novotný, D. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.02.011 · Cited by 15
The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients
Tarighi, B., Kürüm, T., Demir, M., & Azcan, Ş. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70227-1 · Cited by 15
Hypercoagulability Markers in Patients with Peripheral Arterial Disease: Association to Ankle-brachial Index
Lucas, M. A. P., de, C. S. M. E. R., das Chagas, L. S. F., de, C. S. N. C., de Oliveira, S. M., & Ferriani, M. D. G. C. (2008) · Angiology · doi:10.1177/0003319708325444 · Cited by 15
“In individuals who had suffered MI, fibrinolytic activity is diminished because of increased PAI-1 activity.(14) Thrombomodulin (TM) is linked to natural anticoagulation mechanisms considering that protein C activation depends on TM expression and endothelial protein C receptor on the surface of endothelial cells.”
BackgroundResult
Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease
Simone, T. M. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000125 · Cited by 15
“PAI-1 increases precede MI and predispose patients to MI independent of other risk factors [36,37].”
Background
Palmolein and olive oil consumed within a high protein test meal have similar effects on postprandial endothelial function in overweight and obese men: A randomized controlled trial
Stonehouse, W., Brinkworth, G. D., & Noakes, M. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.009 · Cited by 15
“Both tPA antigen and PAI-1 have been associated with increased risk of CHD [46,47].”
Background
Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism Modulates Coronary Release of Tissue Plasminogen Activator in Response to Bradykinin
Ohira, N., Matsumoto, T., Tamaki, S., TAKASHIMA, H., Tarutani, Y., Yamane, T., Yasuda, Y., & Horie, M. (2004) · Hypertension Research · doi:10.1291/hypres.27.39 · Cited by 15
“In the present study, ACE polymorphism had no influence on circulating PAI-1 antigen levels, although several studies have reported that elevated PAI-1 levels were observed in subjects with the ACE DD genotype (27, 28) and were related to an increased risk of cardiovascular thrombotic events (29).”
Background
The assessment of vascular function during dietary intervention trials in human subjects
McCall, D. O., McKinley, M. C., Noad, R., McKeown, P. P., McCance, D. R., Young, I. S., & Woodside, J. V. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511002996 · Cited by 14
Endothelial METTL3 (Methyltransferase-Like 3) Inhibits Fibrinolysis by Promoting PAI-1 (Plasminogen Activator Inhibitor-1) Expression Through Enhancing Jun Proto-Oncogene N6-Methyladenosine Modification
Bai, Q., Lu, Y. W., Chen, Y., Zhang, H., Zhang, W., Wu, H., & Wen, A. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316414 · Cited by 14
Administration of testosterone improves the prothrombotic and antifibrinolytic parameters associated with its deficiency in an orchidectiomized rat model
Alqahtani, S. A., & Alhawiti, N. M. (2018) · Platelets · doi:10.1080/09537104.2018.1499886 · Cited by 16
Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes
Pratte, K., Barón, A. E., Ogden, L. G., Hassell, K. L., Rewers, M., & Hokanson, J. E. (2008) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.07.002 · Cited by 14
“In addition, medications that affect insulin sensitivity (Juhan-Vague et al., 1987; Nagi & Yudkin, 1993) and RAS (Kerins et al., 1995; Vaughan, 1998; Vaughan et al., 1995) can modulate PAI-1 levels.”
Background
TNF-α induces early growth response gene-1 expression via ERK1/2 activation in endothelial cells
Cao, Y., Zhang, J., Meng, X., & Wang, D. (2011) · Acta Diabetologica · doi:10.1007/s00592-010-0248-7 · Cited by 14
Effect of Estrogen Therapy on Insulin Resistance and Plasminogen Activator Inhibitor Type 1 Concentrations in Postmenopausal Women
Saucedo, R., Basurto, L., Zárate, A., Martínez, C., Hernández, M., & Galván, R. E. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000099148 · Cited by 14
“]as follows:HOMA-IR = fasting insulin (µU/ml) × fasting glucose (mmol/l)/22.5. Hemostatic Marker Levels of PAI-1 antigen were assessed using an immunoenzymatic method (Imulise™ PAI-1®, Biopool, Ventura, Calif., USA). The intra- and interassay CV were 4.5 and 7.4p. Quality control for the assays in our laboratory has b…”
MethodInfluential
Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus
Zimering, M. B., Anderson, R. J., Ge, L., & Moritz, T. E. (2010) · Metabolism · doi:10.1016/j.metabol.2010.02.003 · Cited by 12
Allelic Frequency of the PAI‐1 4G/5G Promoter Polymorphism in Patients with Type 2 Diabetes Mellitus and Lack of Association with PAI‐1 Plasma Levels
Zietz, B., Buechler, C., Drobnik, W., Herfarth, H. H., Schölmerich, J., & Schäffler, A. (2004) · Endocrine Research · doi:10.1081/erc-200035728 · Cited by 14
“Low plasma fibrinolytic activity due to increased PAI-1 levels precedes coronary artery disease (1,2) and even predicts the occurrence of first acute myocardial infarction (3,4) and reinfarction as well (5).”
Background
Association of plasminogen activator inhibitor-1 with insulin resistance in Japan where obesity is rare
Nakamura, T., Adachi, H., Hirai, Y., Satoh, A., Ohuchida, M., & Imaizumi, T. (2003) · Metabolism · doi:10.1053/meta.2003.50027 · Cited by 14
Effects of Angiotensin Converting Enzyme Inhibitors on Thrombotic Mediators: Potential Clinical Implications
Kothari, S. A., Le, M. K., & Gandhi, P. J. (2003) · Journal of Thrombosis and Thrombolysis · doi:10.1023/b:thro.0000011379.68077.64 · Cited by 14
Changes in Hemostatic Variables Induced by Estrogen Replacement Therapy: Comparison of Transdermal and Oral Administration in a Crossover-Designed Study
Fait, T., Vrablı́k, M., Zizka, Z., & Kostirova, M. (2007) · Gynecologic and Obstetric Investigation · doi:10.1159/000107492 · Cited by 14
Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women
Duschek, E. J. J., Stehouwer, C. D. A., Roo, G. W. D. V.-D., Schalkwijk, C., Lambert, J., & Netelenbos, J. C. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01156.x · Cited by 14
The role of fibrinolysis in the development of prediabetes-associated coronary heart disease: a focus on the plasminogen activator inhibitor -1 and its potential use as a predictive marker in diet-induced prediabetes
Gumede, N. P., & Khathi, A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1256427 · Cited by 13
The Influence of Hyperthyroidism on the Coagulation and on the Risk of Thrombosis
Antonijevic, N. M., Matić, D., Beleslin, B. N., Miković, D., Leković, Ž., Marjanovic, M. M., Ušćumlić, A., Birovljev, L., & Jakovljević, B. D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061756 · Cited by 13
A Case-control Study in an Orcadian Population Investigating the Relationship between Human Plasma N-glycans and Metabolic Syndrome
McLachlan, F., Timofeeva, M. N., Bermingham, M. L., Wild, S. H., Rudan, I., & Lauc, G. (2016) · Journal of Glycomics & Lipidomics · doi:10.4172/2153-0637.1000139 · Cited by 12
Elevated Plasma Levels of PAI-1 Predict Cardiovascular Events and Cardiovascular Mortality in Prevalent Peritoneal Dialysis Patients
Arikan, I. H., Koç, M., Tuğlular, S., Ozener, C. I., & Akoğlu, E. (2009) · Renal Failure · doi:10.1080/08860220902963772 · Cited by 13
Circadian rhythm and cardiovascular disorders
Jain, M. K., Zhang, L., & Sabeh, M. K. (2014) · ChronoPhysiology and Therapy · doi:10.2147/cpt.s44805 · Cited by 14
High dose of red wine elicits enhanced inhibition of fibrinolysis
Kiviniemi, T., Saraste, A., Lehtimäki, T. J., Toikka, J., Saraste, M., Raitakari, O. T., Pärkkä, J. P., Hartiala, J., Viikari, J. S. A., & Koskenvuo, J. W. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328320ad1b · Cited by 13
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects
Al-Hamodi, Z. H., Saif-Ali, R., Ismail, I. S., Ahmed, K. A., & Muniandy, S. (2011) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.11-48 · Cited by 13
Prognostic Value of Multiple Biomarkers in American Indians Free of Clinically Overt Cardiovascular Disease (from the Strong Heart Study)
Kizer, J. R., Krauser, D. G., Rodeheffer, R. J., Burnett, J. C. J., Okin, P. M., Roman, M. J., Umans, J. G., Best, L. G., Lee, E. T., & Devereux, R. B. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.03.026 · Cited by 13
Green tea polyphenols inhibit plasminogen activator inhibitor-1 expression and secretion in endothelial cells
Liu, J., Ying, C., Meng, Y., Yi, W., Fan, Z., Zuo, X., Tian, C., & Sun, X.-F. (2009) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32832e05f0 · Cited by 13
Association of pulse pressure with fibrinolysis in patients with type 2 diabetes
Wakabayashi, I., & Masuda, H. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2007.02.014 · Cited by 12
Regulatory Mechanism of MicroRNA-30b on Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
Wang, W., & Jia, L. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105553 · Cited by 12
Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors
Hrovat, K., Likozar, A. R., Zupan, J., & Šebeštjen, M. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9070211 · Cited by 13
“In prospective and casecontrol studies, PAI-1 levels were found to be associated with the risk of first [44] and recurrent acute myocardial infarction [45].”
Background
Use of Mouse Models to Study Plasminogen Activator Inhibitor-1
Declerck, P. J., Gils, A., & Taeye, B. M. D. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386471-0.00005-5 · Cited by 12
Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: the Guangzhou Biobank Cohort Study-CVD
Xu, L., Jiang, C. Q., Lam, T. H., Bao, B., Cheng, K. K., & Thomas, G. N. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03948.x · Cited by 12
Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency
Brown, N. J., Bradford, J., Wang, Z., Lea, W. B., Ma, L., Ma, J., Vaughan, D. E., & Fogo, A. B. (2007) · Kidney International · doi:10.1038/sj.ki.5002268 · Cited by 12
Do plasminogen activator inhibitor (PAI‐1) or tissue plasminogen activator PAI‐1 complexes predict complications in Type 1 diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study
Bosnyák, Z., Forrest, K. Y. Z., Maser, R. E., Becker, D. J., & Orchard, T. J. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00898.x · Cited by 12
Cardiovascular Risk Associated with Interactions among Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems
Bentley, J. P., Asselbergs, F. W., Coffey, C. S., Hebert, P. R., Moore, J. H., Hillege, H. L., & van Gilst, W. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012757 · Cited by 12
“Factors that increase PAI-1 levels and decrease t-PA levels may increase the risk of thrombosis as both are risk markers for cardiovascular disease [2,3].”
Background
Regulatory role of microRNA-30b and plasminogen activator inhibitor-1 in the pathogenesis of cognitive impairment
Li, X., Gao, Y., Meng, Z.-Y., Zhang, C., & Qi, Q. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3162 · Cited by 12
Thrombophilia in coronary artery disease: a double jeopardy.
Mohanty, D., Ghosh, K., Khare, A., & Kulkarni, B. P. (2004) · PubMed · Cited by 12
Brachial Artery Flow-Mediated Vasodilation Is Correlated with Coronary Vasomotor and Fibrinolytic Responses Induced by Bradykinin
Tarutani, Y., Matsumoto, T., TAKASHIMA, H., Yamane, T., & Horie, M. (2005) · Hypertension Research · doi:10.1291/hypres.28.59 · Cited by 12
“An increase in circulating tPA levels has been shown to be due to responses to increased endogenous PAI-1, and predicts future myocardial infarction (6).”
Background
Ozonized autohaemotransfusion and fibrinolytic balance in peripheral arterial occlusive disease
Coppola, L., Lettieri, B., Cozzolino, D., Luongo, C., Sammartino, A., Guastafierro, S., Coppola, A., Mastrolorenzo, L., & Gombos, G. (2002) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200212000-00002 · Cited by 12
Atherosclerosis, cigarette smoking, and endogenous fibrinolysis: Is there a direct link?
Chia, S., & Newby, D. E. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0038-y · Cited by 12
“And although elevated basal plasma tPA concentrations would be anticipated to protect against subsequent coronary events, higher total plasma tPA antigen concentrations positively predict future coronary events in epidemiologic studies of patients with ischemic heart disease [6,7] and in healthy populations [8, 9 ].”
Background
Increased Plasma Plasminogen Activator Inhibitor‐1 Levels: A Possible Marker of Hypertensive Target Organ Damage
Diamantopoulos, E. J., Andreadis, E. A., Vassilopoulos, C., Theodorides, T. G., Giannakopoulos, N. S., Chatzis, N. A., & Christopoulou-Kokkinou, V. (2003) · Clinical and Experimental Hypertension · doi:10.1081/ceh-120017736 · Cited by 12
“This could be related to the adverse prognosis carried by the fibrinolytic disturbance (3, 4).”
Background
The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Traish, A. M., Abu-Zahra, H., & Guay, A. T. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786898699 · Cited by 12
“Serum levels of DHEAS did not change as vWF, PAI-1 and tPA changed [146].”
Background
Emerging Thrombotic Effects of Drug Eluting Stents
Lang, N. N., & Newby, D. E. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255308.41576.ae · Cited by 12
Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration
Lanktree, M. B., Johansen, C. T., Anand, S. S., Davis, A. D., Miller, R., Yusuf, S., Hegele, R. A., & on behalf of the SHARE, A. S.-A. I. (2010) · Blood · doi:10.1182/blood-2010-02-269902 · Cited by 11
Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity
Sillen, M., Weeks, S. D., Strelkov, S. V., & Declerck, P. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165859 · Cited by 11
Relationship of glucose concentrations with PAI‐1 and t‐PA in subjects with normal glucose tolerance
Heldgaard, P. E., Sidelmann, J. J., Hindsberger, C., Olivarius, N. D. F., Henriksen, J. E., & Gram, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01924.x · Cited by 11
“Furthermore, elevated levels of PAI-1 were found to predict a first acute myocardial infarction in both men and women [ 23 ].”
Background
Osteonecrosis of the Jaws in Patients with Hereditary Thrombophilia/Hypofibrinolysis—From Pathophysiology to Therapeutic Implications
Bădescu, M. C., Rezuş, E., Ciocoiu, M., Bădulescu, O. V., Butnariu, L. I., Popescu, D., Bratoiu, I., & Rezuș, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020640 · Cited by 12
“Elevated PAI-1 levels are a risk factor for VTE (especially in Asians [100]), myocardial infarction [131] and stroke [132].”
Background
In vitro effects of detergent sclerosants on fibrinolytic enzymes and inhibitors
Parsi, K., Exner, T., Ma, D. D. F., & Joseph, J. E. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.06.028 · Cited by 11
Sex-related differences in the associations between hyperleptinemia, insulin resistance and dysfibrinolysis
Eriksson, M. A., Rask, E., Johnson, O., Carlström, K., Åhrén, B., Eliasson, M., Boman, K., & Söderberg, S. (2008) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e3283099046 · Cited by 11
Self-citation
The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis
Ardigò, D., Franzini, L., Valtueña, S., Numeroso, F., Piatti, P. M., Monti, L. D., Reaven, G. M., & Zavaroni, I. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.06.026 · Cited by 11
Fiber Intake and Plasminogen Activator Inhibitor-1 in Type 2 Diabetes: Look AHEAD (Action for Health in Diabetes) Trial Findings at Baseline and Year 1
Belalcazar, L. M., Anderson, A., Lang, W., Schwenke, D. C., Haffner, S. M., Yatsuya, H., Rushing, J., Vitolins, M. Z., Reeves, R., Pi-Sunyer, X., et al. (2014) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2014.06.357 · Cited by 11
Increased heart rate is associated with a prothrombotic state: The Framingham Heart Study
Tofler, G. H., Massaro, J. M., Levy, D. A., Sutherland, P. A., Buckley, T. A., & D’Agostino, R. B. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316679902 · Cited by 11
Risk factors for cardiovascular disease in renal transplant recipients: new insights
Marcucci, R., Zanazzi, M., Bertoni, E., Brunelli, T., Fedi, S., Evangelisti, L., Pepe, G., Rogolino, A. A., Prisco, D., Abbate, R., et al. (2000) · Transplant International · doi:10.1007/s001470050375 · Cited by 11
Genetic and metabolic determinants of increased plasma plasminogen activator inhibitor-1 activity in children with renal transplants
Ald�miz-Echevarr�a, L., Sanjurjo, P., Vallo, A., Aguirre, M., P�rez-Nanclares, G., Berges-Gimeno, P., Rueda, M., Ruiz, J. I., & Rodr�guez-Soriano, J. (2003) · Pediatric Nephrology · doi:10.1007/s00467-003-1157-6 · Cited by 11
“An increased plasma PAI-1 has been proposed as a tool to identify adult subjects who may later develop type 2 diabetes [35] or present some type of occlusive vascular disease [ 36 ].”
Method
Difference in fibrinolytic activity between multivessel coronary spasm and one-vessel coronary spasm
Ogawa, H., Suefuji, H., Takazoe, K., Soejima, H., Sakamoto, T., Miyamoto, S., Kaikita, K., Yoshimura, M., Kugiyama, K., & Yasue, H. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00614-1 · Cited by 11
Low level of tissue plasminogen activator activity in non‐diabetic patients with a first myocardial infarction
Lundblad, D., Dinesen, B., Rautio, A., Røder, M. E., & Eliasson, M. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01507.x · Cited by 11
Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE)
González-Mendoza, D. E., Fernández-Nogueira, F., Uribe, M., Chávez-Tapia, N. C., & Nuño‐Lámbarri, N. (2025) · Thrombosis Research · doi:10.1016/j.thromres.2025.109395 · Cited by 11
Migration at early age from a high to a lower coronary heart disease risk country lowers the risk of subclinical atherosclerosis in middle‐aged men
Jartti, L., Rönnemaa, T., Raitakari, O. T., Hedlund, E., Hammar, N., Lassila, R., Marniemi, J., Koskenvuo, M., & Kaprio, J. A. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02018.x · Cited by 10

Authors: Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G.
Affiliations: From the Department of Medicine (A.M.T.), Department of Clinical Chemistry (T.K.N.), and Departments of Nutritional Research and Pathology (G.H.), Umeå University Hospital; Department of Medicine-Geriatric, Skellefteå County Hospital (J.-H.J., K.B.) and Department of Epidemiology and Public Health (L.W.), University of Umeå; and Department of Medicine, Luleå Hospital (F.H.), Sweden.
University Hospital of Umeå (SE)
ORCID: Boman, Kurt
Weinehall, Lars
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1998-11-24
Volume: 98
Issue: 21
Pages: 2241-2247
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.98.21.2241
OpenAlex: W1976057876
Cited by: 602
References: 30
Citations by year: 2026: 3 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 19 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 14 · 2017: 7 · 2016: 17 · 2015: 12 · 2014: 27 · 2013: 20 · 2012: 19
FWCI: 10.91
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Umeå Universitet
Topics: Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Hematology › Blood properties and coagulation
Keywords: plasminogen activator inhibitor-1, tissue plasminogen activator, acute myocardial infarction, von Willebrand factor, thrombomodulin, fibrinolysis, coronary artery disease, cardiovascular risk prediction, sex differences, plasma biomarkers
MeSH terms: Adult, Age Factors, Female, Fibrinolysis, Humans, Middle Aged, Myocardial Infarction, Tissue Plasminogen Activator, Predictive Value of Tests, Prospective Studies, Risk Factors, Sex Factors, Sweden, Biomarkers, Plasminogen Inactivators, Incidence, Case-Control Studies, Dehydroepiandrosterone Sulfate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks